Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
about
Antiglucocorticoid treatments for mood disordersOral contraceptives containing drospirenone for premenstrual syndromeOral contraceptives containing drospirenone for premenstrual syndromeAntiglucocorticoid treatments for mood disordersThe role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatmentReproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?Gender-related Differences in Food Craving and ObesityContraception technology: past, present and futureHormonal anticonception anno 2013: a clinician's viewPerceived stress and severity of perimenstrual symptoms: the BioCycle Study.The association between drospirenone and hyperkalemia: a comparative-safety studyHormone treatment of depression.Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorderHormonal therapies in acne.Treatment of depression associated with the menstrual cycle: premenstrual dysphoria, postpartum depression, and the perimenopauseReproductive hormonal treatments for mood disorders in women.Premenstrual Dysphoric Disorder: Recognition and TreatmentAlgorithm for treatment of premenstrual syndromes (PMS): experts' recommendations and limitations.Added benefits of drospirenone for compliance.Mindfulness-based Stress Reduction as a Promising Intervention for Amelioration of Premenstrual Dysphoric Disorder SymptomsPhysiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills.Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol.Premenstrual dysphoric disorder: burden of illness and treatment update.Premenstrual syndrome symptomatology among married women of fertile age based on methods of contraception (hormonal versus non-hormonal methods of contraception)Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder).Drospirenone: a novel progestin.A reproductive subtype of depression: conceptualizing models and moving toward etiology.The association of migraine with menstrually related mood disorders and childhood sexual abuse.Association of hormonal contraceptive use with reduced levels of depressive symptoms: a national study of sexually active women in the United States.ISPMD consensus on the management of premenstrual disorders.Adverse mood symptoms with oral contraceptives.Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder.Paroxetine use in the treatment of premenstrual dysphoric disorder.Drospirenone in the treatment of severe premenstrual cerebral edema in a woman with antiphospholipid syndrome, lateral sinus thrombosis, situs inversus and epileptic seizures.Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review.Sex Hormones and Processing of Facial Expressions of Emotion: A Systematic Literature Review.Non-contraceptive benefits of oral contraceptives
P2860
Q24187372-82778D00-A65B-46C6-9F66-5C2964E1765DQ24203717-BBCCBC7C-0DF2-4BE8-891D-9DB659D9EFA4Q24240981-41359949-91B0-4B85-947C-EA2EF773A469Q24242845-4C2775B7-A524-4510-ABB5-FF4D4F9AE339Q24561815-06E9B6A5-73F1-46DB-AE80-F9CDB80F395BQ24650090-EC952CB8-6B15-46EF-860B-E9B81792509AQ26746183-F3372CD1-FCD2-4A70-96E1-6B92DD0DA286Q26849373-C1F16CBB-F3A1-47D4-B04C-F7F124B3A1F8Q28384050-4C7449C6-739C-414A-B344-6E44FECDE906Q33874964-C216DDFC-D996-4880-BD96-47AF25801383Q34114759-7B95154F-619F-49AA-AE10-D08ABED4D518Q34177698-9DEF15D9-1C26-4CB0-B9F1-59B1F85FD681Q34272049-0889E635-E993-49E6-B0FD-A5C565BEAE2DQ34706886-C5166BA5-447A-4FBB-8836-D57AEE05BD62Q35236462-59883C9B-CF48-48B7-84A3-A53C1E066B3EQ35236472-D717E9AC-5032-4791-A215-AB9F921A6F45Q35779791-AF4FC743-9A90-447F-817A-D275685E0274Q36169643-7C48D273-548E-4C5F-BF15-1CE93E9711FCQ36276334-E3622D80-00B1-4ECA-8046-CABC9D7734C3Q36295297-2C98E5E3-C53D-4D11-A3FA-33DA939496D0Q36573746-1ACEF347-34FC-466C-A3FB-2F9833880A6DQ36642976-D64B7FC8-2118-470B-BC02-EDDD5573479BQ36737964-9DC1CDB3-FEA3-46A0-9B74-3C7DA768362AQ36779937-57B1ED80-90FB-4F9C-804F-9A8BF0C6A75AQ36801465-E3D613F0-C3C0-4E70-83C8-B60B1B3FD19AQ36808051-11DC1106-58C0-4679-A10A-3C6E7E69BF29Q37089316-EC910CDE-870B-484E-9762-2B997B2F0896Q37208182-25A680F4-E454-4E7F-9D13-DB5189DD2B5EQ37463944-82F64CC0-0303-423A-9893-874978B0D8A8Q37638987-0CC77036-4D7A-4A6C-972C-F24A1CC0EF0EQ37963994-1ABB8266-5144-4013-82BB-4A2EB60CD1A4Q40234284-E5475251-4D7E-4ED5-8F7B-C37C33EB7DD8Q42598362-54A2417B-E2AE-41CD-9AE6-DD3A9639EAA0Q43267026-ED9546BF-E781-4553-9466-237C7644AFC3Q43267054-9470A82B-2469-437F-9089-2E677246B440Q46864414-6E421B58-2EE3-4F6F-8BCD-C82913C086FAQ48113811-76CBBDA2-BF7B-4134-A832-979ABD3FD813Q49540101-85A3392E-8ED1-46A9-A39D-39854BAC80D1Q52562664-30CF27E9-CA14-49F5-B401-AF859635A1BFQ56058552-93D591D2-088D-4260-B757-0BB0D9DE7FD7
P2860
Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Evaluation of a unique oral co ...... emenstrual dysphoric disorder.
@en
type
label
Evaluation of a unique oral co ...... emenstrual dysphoric disorder.
@en
prefLabel
Evaluation of a unique oral co ...... emenstrual dysphoric disorder.
@en
P2093
P1476
Evaluation of a unique oral co ...... emenstrual dysphoric disorder.
@en
P2093
E W Freeman
PMS/PMDD Research Group
T Pearlstein
P304
P356
10.1089/15246090152543148
P577
2001-07-01T00:00:00Z